Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Beavis

Showing results (61-70 of 92) with videos related to

Pageof 10
Sort By:
The EMBO Journal|December 6, 2019
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumoursFlorian Wiede, Kun-Hui Lu, Xin Du, et al.
Cell Reports|March 2, 2017
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1Simon J Hogg, Stephin J Vervoort, Sumit Deswal, et al.
Science Immunology|May 20, 2018
Tumor immune evasion arises through loss of TNF sensitivityConor J Kearney, Stephin J Vervoort, Simon J Hogg, et al.
Science Advances|May 14, 2025
Interleukin-4 modulates type I interferon to augment antitumor immunityHannah V Newnes, Jesse D Armitage, Anthony C Buzzai, et al.
Nature Communications|September 21, 2017
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancerSathana Dushyanthen, Zhi Ling Teo, Franco Caramia, et al.
The Journal of Clinical Investigation|February 7, 2017
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyPaul A Beavis, Melissa A Henderson, Lauren Giuffrida, et al.
Haematologica|June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cellsKelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
Nature Communications|May 29, 2021
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacyLauren Giuffrida, Kevin Sek, Melissa A Henderson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 1, 2020
IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid TumorsLauren Giuffrida, Kevin Sek, Melissa A Henderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2016
Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen SettingClare Y Slaney, Bianca von Scheidt, Alexander J Davenport, et al.
Pageof 10

Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
The EMBO Journal|December 6, 2019
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumoursFlorian Wiede, Kun-Hui Lu, Xin Du, et al.
Cell Reports|March 2, 2017
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1Simon J Hogg, Stephin J Vervoort, Sumit Deswal, et al.
Science Immunology|May 20, 2018
Tumor immune evasion arises through loss of TNF sensitivityConor J Kearney, Stephin J Vervoort, Simon J Hogg, et al.
Science Advances|May 14, 2025
Interleukin-4 modulates type I interferon to augment antitumor immunityHannah V Newnes, Jesse D Armitage, Anthony C Buzzai, et al.
Nature Communications|September 21, 2017
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancerSathana Dushyanthen, Zhi Ling Teo, Franco Caramia, et al.
The Journal of Clinical Investigation|February 7, 2017
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyPaul A Beavis, Melissa A Henderson, Lauren Giuffrida, et al.
Haematologica|June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cellsKelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
Nature Communications|May 29, 2021
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacyLauren Giuffrida, Kevin Sek, Melissa A Henderson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 1, 2020
IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid TumorsLauren Giuffrida, Kevin Sek, Melissa A Henderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2016
Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen SettingClare Y Slaney, Bianca von Scheidt, Alexander J Davenport, et al.
Pageof 10